<DOC>
	<DOCNO>NCT00343499</DOCNO>
	<brief_summary>24 week , single center , prospective , randomize , double-blind treatment study valsartan ( 80 mg/bid , increase 160 mg/bid ) placebo addition general medical therapy patient persistent atrial fibrillation ( AF ) undergo electrical cardioversion restore normal sinus rhythm ( SR ) .</brief_summary>
	<brief_title>The Use DIOVAN Reduce Post-Cardioversion Recurrence Atrial Fibrillation Trial ( DRAFT Trial )</brief_title>
	<detailed_description>To evaluate efficacy valsartan , add standard AF therapy , maintain sinus rhythm extend interval first AF recurrence cardioversion.Evaluate efficacy valsartan , begin prior cardioversion , difficulty ( number total energy CV attempt ) , net rate cardioversion ( SR &gt; 10 minute ) , early AF recurrence rate ( within 24 hour )</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>The patient ( male nonpregnant female ) must &gt; 18 year age Have ECG document AF time enrollment study Require ( schedule ) electrical cardioversion Female patient childbearing potential must document negative pregnancy test index hospitalization . The patient legally authorized representative willing give write informed consent , prior procedure , use ICF approve UCR Institutional Review Board . Surrogate consent must give per CV Research SOP . Have serum potassium level 3.5 5.5 meq/L If diabetic , hemoglobin A1C level &lt; 11 % NYHA III enrol hospitalization heart failure within 6 month current , know EF &lt; 40 % . The patient unable unwilling cooperate study followup procedure . Pregnant and/or lactate woman , woman child bear potential use acceptable mean contraception . Women childbearing potential must use adequate measure contraception ( determined Investigator ) avoid pregnancy highly unlikely conceive study period . Women childbearing potential must negative pregnancy test screen . Participation clinical trial involve investigational market product within 30 day prior entry study . Current diagnosis angina pectoris ( event within period 3 month prior Visit 1 ( V1 ) History current diagnosis symptomatic heart failure ( NYHA class IIIIV ) document ejection fraction &lt; 40 % . Myocardial Infarction within 3 month ; coronary revascularization ( PCI CABG ) , unstable angina within 1 month V1 . Stroke , deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) transient ischemic attack ( TIA ) within 3 month V1 . Substance alcohol abuse within 6 month V1 Known allergy drug administer study ( angiotensin receptor blocker ( ARB ) angiotensin convert enzyme inhibitor ( ACEI ) , Valsartan , amiodarone , flecainide propafenone ) Any contraindication list label warfarin acenocoumarol . Patients treat ARBs ACEI within 1 month V1 Impaired renal function define serum creatinine &gt; 2.5 mg/dL Evidence hepatic disease evidence AST ALT value &gt; 2 time upper limit institution 's normal value . Significant noncardiovascular illness condition likely result severe incapacitation death prior study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>valsartan</keyword>
	<keyword>sinus rhythm</keyword>
	<keyword>persistent atrial fibrillation undergo electrical cardioversion restore normal sinus rhythm</keyword>
</DOC>